...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Tropical Medicine and Hygiene >Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy.
【24h】

Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy.

机译：间质疟原虫疟疾对伯氨喹作为抗复发治疗的反应区域差异。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We used logistic regression to assess effectiveness of primaquine as Plasmodium vivax anti-relapse therapy using data extracted from studies of P. vivax relapses in Brazil, India, and Thailand. The risk of relapse in Thailand was 10 times that in India and twice that in Brazil. In comparison with no primaquine treatment, the risk of relapse decreased by approximately 80% for a total adult primaquine regimen of 210 mg and by > or =95% for regimens of 315 mg and 420 mg. In addition, we used logistic regression to estimate the risk of P. vivax relapse according to weight-based primaquine dose using data from case studies. There was a three-fold increase in the likelihood of successful treatment of each additional milligram of primaquine per kilogram of body weight. Tailoring primaquine therapy to a region requires consideration of factors including body weight, natural relapse rates, and local response to primaquine.
机译：我们使用从巴西，印度和泰国的间日疟原虫复发研究中提取的数据，通过逻辑回归评估伯氨喹作为间日疟原虫抗复发疗法的有效性。泰国的复发风险是印度的十倍，是巴西的两倍。与不使用伯氨喹治疗相比，对于总成人剂量为210 mg的伯氨喹，复发风险降低了约80％，而对于315 mg和420 mg的方案，复发风险降低了≥95％。此外，我们使用基于Logistic回归的案例研究数据，根据基于体重的伯氨喹剂量，估算间日疟原虫复发的风险。成功治疗每公斤体重每增加一毫克伯氨喹的可能性增加了三倍。为某个区域量身定制伯氨喹治疗需要考虑一些因素，包括体重，自然复发率以及对伯氨喹的局部反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号